These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30353992)

  • 1. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
    Kovac RL; Ballash G; Fenger J; London C; Warry E
    J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Cytokeratin 18 and fecal Alpha-1 Antitrypsin concentrations in dogs with osteosarcoma receiving carboplatin chemotherapy.
    Taikowski K; Rudinsky AJ; Louke DS; Warry E; Fenger JM
    Vet Med Sci; 2021 Mar; 7(2):385-392. PubMed ID: 33222415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
    Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
    J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
    J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin depigmentation associated with toceranib phosphate in a dog.
    Cavalcanti JVJ; Hasbach A; Barnes K; Dange RB; Patterson J; Saavedra PV
    Vet Dermatol; 2017 Aug; 28(4):400-e95. PubMed ID: 28164401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
    Chon E; McCartan L; Kubicek LN; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
    Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
    J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.
    Hume KR; Rizzo VL; Cawley JR; Balkman CE
    J Vet Intern Med; 2018 Jan; 32(1):377-383. PubMed ID: 29193327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
    Mitchell L; Thamm DH; Biller BJ
    J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
    Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
    Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
    Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
    Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.